These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10979204)

  • 1. Current status and future issues in the treatment of HIV-1 infection.
    Matsushita S
    Int J Hematol; 2000 Jul; 72(1):20-7. PubMed ID: 10979204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-human immunodeficiency virus drug combination strategies.
    Vandamme AM; Van Vaerenbergh K; De Clercq E
    Antivir Chem Chemother; 1998 May; 9(3):187-203. PubMed ID: 9875399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term suppression of HIV infection: benefits and limitations of current treatment options.
    Sension MG
    J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
    Wilson LE; Gallant JE
    Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and challenges of antiretroviral research and therapy.
    Esté JA; Cihlar T
    Antiviral Res; 2010 Jan; 85(1):25-33. PubMed ID: 20018390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV infection and advanced age emerging epidemiological, clinical, and management issues.
    Manfredi R
    Ageing Res Rev; 2004 Jan; 3(1):31-54. PubMed ID: 15164725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of antiretroviral therapy: challenges and needs.
    Moreno S; López Aldeguer J; Arribas JR; Domingo P; Iribarren JA; Ribera E; Rivero A; Pulido F;
    J Antimicrob Chemother; 2010 May; 65(5):827-35. PubMed ID: 20228080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Salvage therapy in HIV infection].
    Salzberger B
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():52, 54-5, 57. PubMed ID: 15373050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.